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Introduction
Despite recent progress in molecular genetics that has provided a basis for development of targeted therapeutic interventions, effective molecular therapies for breast cancer are still scarce. Given our limited ability to cure advanced breast cancer, development of new treatment modalities is of paramount importance. One such approach is gene therapy.
Success of gene therapy depends on the ability to identify efficient 'killer genes' and to target their expression selectively to cancer cells. Among promising 'killer genes' are those that induce programmed cell death (apoptosis). Apoptosis is a process employed by multicellular organisms to eliminate redundant, damaged or potentially harmful cells. Triggering extrinsic or intrinsic pathways of apoptosis leads to increased expression and/ or activity of proapoptotic regulators, thus inducing cell death. Chemotherapy and radiation therapy have been shown to work predominantly via induction of apoptosis. 1, 2 This natural killing ability of proapoptotic genes makes them attractive candidates for cancer gene therapy. A potential limitation in the use of proapoptotic genes as 'killers' is that their activity is tightly regulated by post-translational modification and subcellular localization. We therefore searched for a proapoptotic gene that does not require additional modification for full activity and identified tBid as one possible candidate.
tBid is a proapoptotic member of the bcl-2 family of programmed cell death regulators. tBid (truncated Bid) is generated from its precursor, Bid, by activated caspase 8, in response to stimulation of death receptors. Active tBid translocates into mitochondria where it activates the intrinsic pathway of apoptosis. 3 To direct tBid expression to cancer cells, we utilized transcriptional targeting. This approach exploits the observation that expression of many genes is preferentially upregulated in cancer cells at the transcriptional level. Promoters of these genes are used to drive transcription of the 'killer genes' to selectively eliminate cancer cells. We selected three such promoters for the current study: those of the Survivin, hTERT and Muc1 genes.
Survivin, a member of the IAP antiapoptotic gene family, is highly and consistently overexpressed in neoplastic cells of diverse origin. [4] [5] [6] [7] [8] Its expression correlates with poor prognosis in a majority of cancer types investigated. [9] [10] [11] [12] Survivin is undetectable in normal adult tissues except small proportions of CD34 þ hematopoietic cells, 13 T-lymphocytes 14, 15 and colonic mucosa. 15 In breast neoplasms, Survivin was detected in 70% of samples. 16 Its expression is at least partially regulated at the transcriptional level. In vivo analysis of the Survivin promoter demonstrated that it was preferentially active in tumor cells in vitro and in vivo. [17] [18] [19] The hTERT gene encodes human telomerase reverse transcriptase, the catalytic subunit of human telomerase. Telomerase activity is detected in a high proportion of human tumors and is absent from a majority of normal adult cells, with the exception of a fraction of actively proliferating hematopoietic, epithelial and germ cells. 20, 21 Evaluation of malignant breast neoplasms demonstrated varying levels of telomerase enzymatic activity in 72-96% of samples. 22, 23 hTERT expression is at least in part controlled at the transcriptional level. 24 The hTERT promoter was shown to be effective in driving tumorspecific gene therapy in telomerase-positive neoplastic cell lines. [25] [26] [27] [28] DF3/Muc1 is a gene normally expressed in small subpopulations of epithelial cells from various tissues. It is overexpressed in up to 70% of breast tumors. 29, 30 The Muc1 promoter was shown to target b-galactosidase expression to Muc1-positive breast cancer cells both in vitro and in vivo.
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The goals of current study were to characterize tumoricidal activity of tBid in a panel of breast cancer cell lines and to target expression of tBid to cancer cells using the promoters of the hTERT, Survivin and Muc1 genes.
Materials and methods

Cell lines and reagents
Human breast cancer cell lines MCF-7, CAMA-1, HCC 1937, MDA-MB-231, T-47D and AU 565 and 'normal' nontumorigenic mammary epithelial cell line MCF-10A were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in RPMI 1640 (T-47D, AU-562 and HCC 1937), a-MEM (MCF-7 and CAMA-1), Leibovitz's-L15 (MDA-MB-231) or human mammary epithelial cell medium from Clonetic (MCF-10A) with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml) at 371C. Except for MDA-MB-231, all cell lines were grown in a humidified atmosphere with 5% CO 2 .
Reagents used in the study were obtained from the following companies: Plasmids and cloning pRL-TK and pSV40-b-galactosidase were purchased from Promega. Bid and Bax cDNA were obtained from ATCC Mammalian Gene Collection and subcloned into pcDNA3.1 þ and IRES2-EGFP vectors to produce CMV-Bid and -Bax and IRES-Bid and -Bax.
tBid (amino acids 60-195, bases 322-732) was amplified by PCR using the following primers:
The forward primer included a Kozac sequence/ATG for optimal translation (indicated in lower case). The resultant PCR product was cloned into T-Vectort, verified by sequencing and subsequently subcloned into pcDNA3.1 þ and IRES2-EGFP vectors to produce CMV-tBid and IRES-tBid, respectively. pp76, containing the hTERT promoter from position À1375 to position þ 77 (relative to the transcription start site) in the pGL3-Basic vector (containing the firefly luciferase coding sequence) was kindly provided by Dr Satoru Kyo (Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Ishikawa, Japan). It was digested with MluI/PstI, blunt-ended and re-closed to delete an XbaI site to produce hTERT-Luc. Luciferase activity of the resultant construct, as tested in our panel of breast cancer cell lines, did not differ from that of pp76 (data not shown).
The Survivin promoter (nucleotides 1821-2800, accession U75285) was amplified by PCR from HeLa genomic DNA using primers described by Hoffman et al.:
The PCR product was first cloned into T-Vectort (Promega) and subsequently subcloned into the pGL3-Basic vector to produce Survivin-Luc. The fidelity of PCR cloning was verified by sequencing.
The Muc1 promoter was obtained from InVivogen and subcloned as an NcoI-SpeI fragment into pGL3-Basic to produce Muc-Luc.
To produce TERT-tBid, Sur-tBid and Muc-tBid, the XbaI-HindIII fragment of TERT-Luc, Survivin-Luc and Muc-Luc, containing the luciferase coding sequence, was replaced with an XbaI-HindIII fragment from CMV-tBid, containing the tBid coding sequence.
To produce CMV promoter-guided luciferase to be used as surrogate 'killer' control, the luciferase gene was cut out of pGL3-Basic and subcloned into pcDNA3.1 and IRES2-EGFP vectors (CMV-Luc and IRES-Luc, respectively).
Transfections and reporter assays
Transient transfections were performed with FuGENE 6 transfection reagent according to the manufacturer's protocol. Briefly, 5 Â 10 4 cells/well were plated in 24-well plates and incubated overnight. For promoter activity studies, promoter-firefly luciferase plasmids (100 ng) were cotransfected with pRL-TK (Promega) expressing Renilla Targeted gene therapy with tBid I Kazhdan et al luciferase as an internal control. The ratio of promoterfirefly luciferase to pRL-TK was 1:1. All assays were performed in duplicate and repeated at least twice. After 36 h, the dual luciferase assay was performed using Promega dual-luciferase reporter assay system according to the manufacturer's protocol. Results are presented as a ratio of firefly/Renilla luciferase activity (FL/ RL Â 100%). For cell survival experiments, two approaches were used. In the first, 5 Â 10 4 cells in duplicate wells were transfected with 100 ng of a tBid-expressing plasmid together with 100 ng of plasmid pSV40-b-galactosidase, which expresses b-galactosidase under control of the SV40 early promoter. The plasmids expressing firefly luciferase in place of tBid, under control of the corresponding promoter, served as a 'surrogate killer gene' control. bGalactosidase activity was measured with a luminescent b-gal detection kit 36 h later. Relative cell survival was estimated as a percent of b-galactosidase reporter activity in tBid-transfected versus luciferase-transfected cultures. When combinations of the tBid-containing constructs under control of different promoters were examined, 100 ng of each promoter-tBid construct was transfected per well. Combination of the corresponding promoterluciferase constructs served as control.
In the second approach, cells were transfected with IRES-tBid. IRES-Luc served as a surrogate killer gene control. After 36 h, cells were harvested and incubated with phycoerythrin-labeled Annexin V as per the manufacturer's protocol. Proportions of GFP-and Annexin V-positive cells were determined by FACS.
Western blotting
Exponentially growing cells were lysed in lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 1 mM phenylmethylsulfonyl fluoride). Whole-cell lysates were sonicated to shear released genomic DNA, and protein concentrations were determined using the BSA protein assay kit (Pierce, Rockford, IL). A 25 mg portion of whole-cell protein lysate from each sample was diluted in 25 ml of SDS loading buffer (4% SDS, 2% glycerol, 0.01% bromphenol blue, 4% b-mercaptoethanol and 125 mM Tris-HCl, pH 6.8), incubated for 5 min at 981C and 5 min on ice and then centrifuged at a maximal speed in a microcentrifuge at room temperature. Proteins were resolved on SDS/ polyacrylamide gels (6% for Muc1 determination and 10% for Survivin determination) and transferred to PVDF membranes. Membranes were blocked for 1 h in 5% nonfat dry milk in TBST (10 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween 20) and probed for 2 h with primary antibodies diluted in TBST/5% nonfat dry milk as per the manufacturer's recommendations. Membranes were then washed with TBST and incubated for 1 h with horseradish peroxidase-labeled secondary antibodies. After four washes with TBST, protein expression was determined by chemiluminescence (ECL, Amershan).
Quantitative PCR
Total RNA was first prepared from cells using the RNAeasy kit (Qiagen). cDNA was synthesized using the High Capacity cDNA Archive kit (Applied Biosystems). The hTERT and GAPDH (used as an internal reference) Taqman-MGB qPCR primer sets were obtained as Assays on Demandt and used and analyzed according to the supplier's protocols (Applied Biosystems).
Indirect immunofluorescence AU 565 and CAMA-1 cells were plated at 1 Â 10 5 cells/ well in eight-well LabTek chamber slides (PGC) in full growth medium. After 48 h, cells were washed twice with phosphate-buffered saline (PBS), fixed for 10 min at room temperature in PBS/4% paraformaldehyde (Electron Microscopy Sciences), treated with PBS/0.1 M glycine for 10 min at room temperature and permeabilized by incubating with PBS/0.1% Triton X-100 for 2 min at room temperature. After two additional washes with PBS, slides were incubated with the polyclonal anti-Survivin antibody (1:50 dilution, FL-142; Santa Cruz Biotechnology) in blocking buffer (1% BSA/0.2% Tween 20/PBS) for 1 h at 371C. Slides were washed 3 Â for 5 min each in PBS and incubated with secondary antibody (Cy3-labeled goat anti-rabbit; Amersham Biosciences), diluted 1:1000 in blocking buffer, for 1 h at 371C. For the negative control, incubation with the anti-Survivin antibody was omitted. After washing with PBS, nuclei were stained by incubation with 4 0 ,6-diamidino-2-phenylindole (DAPI) at 50 mg/ml in PBS for 1 min at room temperature. After washing once with PBS, slides were mounted in Vectashield (Vector Laboratories) and analyzed with fluorescent microscopy.
Results tBid under control of CMV promoter is highly efficient in killing breast cancer cells The killing efficiency of tBid in breast cancer cell lines was first determined in cotransfection experiments. Cells were plated in duplicate wells and transfected with CMV-tBid or CMV-luciferase together with a b-galactosidase reporter gene. Cell survival was estimated as percent of bgalactosidase activity in tBid-transfected cultures relative to luciferase-transfected cultures. This approach was selected because of the limited transfection efficiencies of breast cancer cell lines, which ranged between 20 and 30%. Under these circumstances, the majority of cells did not express the 'killer gene' and analysis of the whole population for evidence of apoptosis could not produce accurate results.
Relative cell survival after expression of the CMV-tBid was below 1% in all cell lines tested except MCF-7 ( Figure 1a) . As expected, 'normal' nontumorigenic MCF-10A epithelial cells were equally susceptible to tBidinduced cell death. Tumoricidal activity of CMV-Bax, used as a positive control in parallel cultures, was inferior to that of tBid.
To confirm the results obtained in cotransfection assays and to demonstrate that the observed decrease of the reporter activity in the presence of tBid is due to apoptotic cell death, CAMA-1 cells were transiently transfected with plasmid IRES-tBid. This plasmid contains the CMV promoter, the tBid coding sequence, an internal ribosome entry site (IRES) and the green fluorescence protein (GFP) coding sequence. In transfected cells, tBid and GFP reporter genes are transcribed together as a single bicistronic mRNA and are translated in series, thus eliminating the uncertainty of cotransfection. 
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Activity of hTERT, Survivin and Muc1 promoters in breast cancer cells If tBid is to be used for cancer gene therapy, the high observed cytotoxicity of tBid will require targeting its expression to cancer cells. For this purpose, we selected the promoters of hTERT, Survivin and Muc1 genes, which are considered to be relatively tumor specific. First, we evaluated the activity of these promoters in breast cancer cell lines and in nontumorigenic MCF-10A mammary epithelial cells. As anticipated, the three promoters were active in all breast cancer cell lines tested, but the magnitude of activity, as measured by transient trasnfection of a luciferase reporter construct, varied significantly among the cell lines (Figure 2 ). Low levels of the hTERT, Survivin and Muc1 promoter activity were also detected in the 'normal' MCF-10A cells. In all cell lines, the activity of the tumor-specific promoters was at least two orders of magnitude lower than that of the CMV promoter (data not shown). As none of the promoters was highly active in all cell lines tested, the results presented above indicate that, for an individual patient, success of gene therapy will depend on selecting a promoter that is expected to be active in the patient's tumor. We therefore evaluated expression of Muc1, hTERT and Survivin genes to determine whether gene expression could be used as a predictor of activity of the corresponding promoter in cancer cells.
Expression of hTERT mRNA as determined by quantitative RT-PCR was identified in all breast cancer cell lines tested (Figure 3a) . There was no strict correlation between the endogenous hTERT mRNA level and hTERT promoter activity, as assessed by transient transfection. For example, HCC 1937 and MDA-MB-231 cells had comparable hTERT promoter activity (Figure 2 ), but expression of hTERT mRNA was five-fold higher in MDA-MB-231 cell line (Figure 3a) . The activity of the hTERT promoter in AU 565 cells was 10 Â that in MCF-7 cells even though MCF-7 cells had approximately 20% higher hTERT mRNA levels. The most pronounced discrepancy was present in CAMA-1 cells, which had a Efficiency of tBid under control of tumor-specific promoters in killing breast cancer cells tBid, under control of the strong, constitutively active CMV promoter, efficiently killed all the breast cancer cell lines tested. Given the highly active and nonspecific nature of killing induced by tBid, its use in cancer gene therapy will require targeting its expression to tumor cells. To determine whether the activity of tumor-specific promoters is sufficient to achieve cell killing by tBid, we replaced the luciferase coding sequence in the TERT-Luc, Muc-Luc and Survivin-Luc plasmids, used in the experiments in Figure 2 , with the tBid coding sequence.
Despite significantly lower promoter activity, as measured by transient transfection of a luciferase reporter (Figure 2 ), the Muc1 promoter was generally more efficient in directing cell killing than the hTERT or the Survivin promoters (Figure 4 ). The only exception was cell line MDA-MB-231, which had minimal detectable Muc1 promoter activity ( Figure 2 ) and minimal Muc1 protein detected on Western blot (Figure 3b) .
TERT-tBid efficiently killed CAMA-1 and AU 565 cells (Figure 4) . These two cell lines demonstrated the highest hTERT promoter activity in the luciferase assay (Figure 2 ). TERT-tBid was moderately efficient in killing HCC 1937, MDA-MB-231 and MCF-7 cells, and ineffective in T-47D cells (Figure 4) . The activity of the hTERT promoter was 13-fold lower in T-47D cells than in AU 565 cells (Figure 2) .
The correlation between hTERT promoter activity and killing efficiency was not absolute. For example, activity of the hTERT promoter in T-47D cells did not differ significantly from that in MDA-MB-231 and HCC 1937 cells, but the relative cell survival in the former was over Targeted gene therapy with tBid I Kazhdan et al 80%, while in the latter two, it was on average below 60%.
The same observations were true for the Survivin promoter. Among the cell lines with high promoter activity, the Survivin promoter directed efficient killing of CAMA-1 and MCF-7, but not of AU 565 cells. MDA-MB-231 cells were relatively sensitive to Survivin-tBid while T-47D cells were resistant despite equivalent promoter activity (Figure 4) .
One explanation for the observed discrepancies would be differential tBid sensitivity among the cell lines. This explanation does not seem likely, however, for several reasons. First, all of the above cell lines were equally sensitive to CMV-tBid. Second, all cell lines with the exception of MDA-MB-231 were sensitive to Muc-tBid despite the relatively low Muc1 promoter activity. Third, in AU 565 cells, Sur-tBid was twice less effective than TERT-tBid (Figure 4) , despite comparable activity of Survivin and hTERT promoters in this cell line (Figure 2 ).
An alternative explanation for the differential sensitivity would be heterogeneity of Survivin promoter activity within the same cell line. The luciferase assay, which tests promoter activity in a population of transfected cells, will produce similar results in a cell line in which the Survivin promoter is highly active only in a fraction of cells and in a cell line in which all cells demonstrate moderate promoter activity. To test the possibility that cell-to-cell variation in expression of Survivin (and consequently, cell-to-cell variation in the Survivin promoter activity) might explain the decreased tumoricidal activity of Survivin-tBid, we analyzed Survivin expression in AU 565 and CAMA-1 cells by immunofluorescence. As mentioned above, AU 565 cells are relatively resistant to Survivin-tBid despite high promoter activity, while CAMA-1 cells are sensitive to the same treatment. Expression of Survivin protein in AU 565 cells was indeed heterogeneous, with a significant proportion of Survivin-negative cells. At the same time, all CAMA-1 cells were positive for Survivin ( Figure 5 ).
Discussion
The goal of the presented work was to identify an efficient proapoptotic 'killer gene' and to test the ability of the promoters of hTERT, Survivin and Muc1 genes to target activity of this gene to genetically heterogeneous breast cancer cells. The six cell lines chosen for the study differ in expression of genes relevant to pathogenesis and prognosis of the disease: estrogen receptor (ER), Her2/neu, p53 tumor suppressor and BRCA1 mutations, and amplification of c-myc. This genetically diverse panel represents frequently encountered variants of breast cancer (Table 1) . Significantly, each one of these genes is implicated in modulation of the apoptotic process.
After evaluation of several proapoptotic modulators, we selected tBid, an active fragment of proapoptotic gene Bid, for further study. Under control of the CMV promoter, tBid killed over 99% of the transfected cells in five of the six breast cancer cell lines tested. The efficiency of tBid in killing cancer cells is likely due to the fact that it does not require additional activating modifications to induce an apoptotic response.
To limit tBid expression to cancer cells, we utilized transcriptional targeting. We examined the activity of three tumor-specific promoters, those of the hTERT, Survivin and Muc1 genes, in the breast cancer cell lines. These promoters were selected because their tumor specificity had been confirmed in the in vivo studies [34] [35] [36] and expression of their corresponding proteins had been shown to be elevated in a high proportion of breast tumors. [37] [38] [39] [40] The activity of the hTERT, Survivin and Muc1 promoters varied significantly among the breast cancer The activity of the hTERT promoter, as measured by the ability to direct luciferase expression, also showed incomplete correlation with the endogenous levels of hTERT mRNA, determined by quantitative PCR. For example, hTERT promoter activity measured in AU 565 cells was 13-fold higher than in T-47D cells, but hTERT mRNA levels in these cell lines were comparable. At the same time, hTERT mRNA expression in CAMA-1 cells, which also demonstrated high hTERT promoter activity, was only marginally higher than in telomerase-negative cell lines. High hTERT promoter activity in cell lines with low hTERT expression has been previously reported. 42 This incomplete correlation between exogenous hTERT promoter activity and hTERT mRNA could be explained by recent data, which demonstrate that regulation of the hTERT transcription occurs on several levels. The epigenetic regulation (involving suppression of transcription due to histone deacetylation 42, 43 and activation of transcription as a result of promoter methylation 44 ) would preferentially affect the endogenous hTERT promoter. On the other hand, overexpression of a positive regulator of hTERT transcription, the oncogene c-myc, 45 might activate exogenous hTERT promoter to a greater extent than a repressed endogenous one. The latter could explain high hTERT promoter activity in our CAMA-1 cells, which were shown to have extra c-myc copies. 46 Although incomplete correlation between hTERT expression and exogenous promoter activity raises concerns for the tumor specificity of hTERT-based transcriptional targeting, multiple recent studies of systemic in vivo administration of hTERT-guided therapeutic genes demonstrated lack of toxicity to normal tissues. 47 When tBid was placed under control of the tumorspecific promoters, it efficiently killed breast cancer cells with relatively high activity of the corresponding promoter. The Muc1 promoter was on average more efficient in directing cell destruction than the hTERT and Survivin promoters, despite having significantly lower measured promoter activity. A possible explanation for this result is that expression of both hTERT and Survivin genes is not constitutive and therefore will vary between individual cells within the same cell line. Indeed, transcription of both hTERT and Survivin genes is cell cycle modulated. [48] [49] [50] [51] Therefore, while promoter activity is high in cells passing through the 'permissive' phase of the cycle, it might be low in the 'nonpermissive' phases and in noncycling cells. When such promoter is used to target 'killer gene' expression, only cells passing through the permissive phase of cell cycle will be destroyed. However, cell cycle specificity of the promoter activity is not always retained in tumors. For example, Survivin expression becomes constitutive in cells expressing an oncogenic ras gene. 52 These data could explain why in our experiments, CAMA-1 cells, in which Survivin expression was detected in all cells, were killed to a significantly greater degree than AU 565 cells, which contain a fraction of Survivinnegative cells ( Figure 5 ).
Cells with low tumor-specific promoter activity (Muc1 in MDA-MB-231 cells, hTERT and Survivin in T-47D cells) were not killed by introduction of tBid under control of these promoters. This suggests that normal cells, in which the tumor-specific promoter activity is low, would not be killed by targeted tBid expression. Indeed, the immortal but nontumorigenic MCF-10A cells were resistant to hTERT-tBid and Survivin-tBid. They retained sensitivity to Muc1-tBid, however. The latter finding is not surprising, as these cells, unlike normal breast epithelial cells, express high levels of Muc1 (data not shown) and demonstrate a high level of the Muc1 promoter activity (Figure 2 ).
Our results demonstrate several difficulties in achieving effective transcriptional targeting of breast tumors. First, there is no single promoter that is sufficiently effective in all tumor cell lines so that it could be used universally in patients with breast cancer. Second, the level of expression of the endogenous Survivin and hTERT genes does not reliably predict activity of the corresponding promoters and, consequently, efficiency of the promoter-guided gene therapy. Third, cancer cells are genetically heterogeneous. Individual cells within a given tumor vary significantly in the degree of expression of tumor-and tissue-specific genes. For example, in DF3/Muc1 positive tumors, the fraction of cells expressing the protein varies between patients, with a median of 30%. 53 Tumors are judged Survivin positive when the fraction of positive cells exceeds 11%. 54 In 'positive' tumors that show such cellto-cell variability, it is expected that only the fraction of To overcome these limitations, it might be necessary to use a combinatorial approach to transcriptional tumor targeting, in which several tumor-and/or tissue-specific promoters are used simultaneously or sequentially to direct expression of a killer gene (or genes). This would increase the probability that at least one of the promoters is active in each individual tumor cell. An alternative approach would be to use noninvasive imaging of the patient's tumor to pre-test promoter activity in tumor cells prior to selecting the best-suited construct for gene therapy. Such an approach, using hTERT promoter guiding transcription of the sodium iodide symporter PET reporter gene with subsequent PET scan visualization, has been recently described. 55 
